Lipid Emulsions & Preterm Infant Nutrition: A Review
- A recent review encompassing 29 studies and 2,037 infants examined the effects of different lipid emulsions (LE) on premature babies.
- The research primarily compared fish oil lipid emulsions with non-fish oil versions, and also different types of fish oil LE against each other.
- Most studies involved intravenous feeding for about four weeks, though longer durations were observed in infants with cholestasis or surgical needs. The primary outcome assessed was PNALD/cholestasis, defined...
This review of 29 studies, encompassing over 2,000 preterm infants, investigates the impact of lipid emulsions (LE) on premature babies, with a special focus on fish oil lipid emulsions. The research compared fish oil LE with conventional soybean oil-based versions, evaluating effects on infants, many of whom had liver conditions. While no significant differences where found in the incidence of liver disease infants with existing conditions notably benefited from fish oil LE. Secondary outcomes like retinopathy of prematurity and mortality rates showed no disparities.Future studies with larger groups and consistent methodologies are key to advancing the understanding of lipid emulsions. News Directory 3 covered the findings in detail. Discover what’s next for preterm infant nutrition.
Fish Oil Lipid emulsions Show Promise for Premature infant Health
Updated June 4, 2025
A recent review encompassing 29 studies and 2,037 infants examined the effects of different lipid emulsions (LE) on premature babies. The analysis focused on various types of LE, including those containing fish oil, conventional soybean oil-based emulsions, and choice options.
The research primarily compared fish oil lipid emulsions with non-fish oil versions, and also different types of fish oil LE against each other. Alternative LE where also compared to soybean oil-based LE. The infants studied were generally less than 37 weeks’ gestation, and some had surgical conditions or PNALD/cholestasis, a liver disease associated with prolonged intravenous feeding.
Most studies involved intravenous feeding for about four weeks, though longer durations were observed in infants with cholestasis or surgical needs. The primary outcome assessed was PNALD/cholestasis, defined by conjugated bilirubin levels of 2 mg/dL or higher. Definitions varied across studies, with cut-offs ranging from 1 mg/dL to approximately 3 mg/dL.
In premature infants, the meta-analysis found no significant difference in the incidence of PNALD/cholestasis between fish oil LE and non-fish oil LE when using a 2 mg/dL cut-off. However, when considering any definition of PNALD and focusing on studies with low or unclear risk of bias, there was still no significant difference in cholestasis incidence between the two groups.
Notably, in premature infants with existing PNALD/cholestasis, the meta-analysis indicated considerably less cholestasis with fish oil-LE compared to soybean oil-LE. However, this finding was based on a small number of participants from two studies with methodological differences, increasing uncertainty.
The study also investigated secondary outcomes. The analysis revealed no differences between fish oil LE and non-fish oil LE in severe retinopathy of prematurity. Similarly,no differences were observed in death rates,bronchopulmonary dysplasia,ventilation duration,or other complications.
What’s next
Further research with larger sample sizes and standardized methodologies is needed to confirm the potential benefits of fish oil lipid emulsions for premature infants, particularly those with liver conditions. standardizing the definition of PNALD/cholestasis would also improve the reliability of future studies.